Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 633

1.

New approaches to small cell lung cancer therapy : from the laboratory to the clinic.

Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, Johnson JE, Ju YS, Kang S, Krasnow M, Lee J, Lee SH, Lehman J, Lok B, Lovly C, MacPherson D, McFadden D, Minna J, Oser M, Park K, Park KS, Pommier Y, Quaranta V, Ready N, Sage J, Scagliotti G, Sos ML, Sutherland KD, Travis WD, Vakoc CR, Wait SJ, Wistuba I, Wong KK, Zhang H, Daigneault J, Wiens J, Rudin CM, Oliver TG.

J Thorac Oncol. 2020 Feb 1. pii: S1556-0864(20)30056-3. doi: 10.1016/j.jtho.2020.01.016. [Epub ahead of print] Review.

PMID:
32018053
2.

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y.

J Thorac Oncol. 2020 Jan 28. pii: S1556-0864(20)30026-5. doi: 10.1016/j.jtho.2020.01.005. [Epub ahead of print] Review.

PMID:
32004713
3.

Comprehensive T cell repertoire characterization of non-small cell lung cancer.

Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J.

Nat Commun. 2020 Jan 30;11(1):603. doi: 10.1038/s41467-019-14273-0.

4.

Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies.

Parra ER, Jiang M, Solis L, Mino B, Laberiano C, Hernandez S, Gite S, Verma A, Tetzlaff M, Haymaker C, Tamegnon A, Rodriguez-Canales J, Hoyd C, Bernachez C, Wistuba I.

Cancers (Basel). 2020 Jan 21;12(2). pii: E255. doi: 10.3390/cancers12020255. Review.

5.

PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma.

Tan X, Banerjee P, Pham EA, Rutaganira FUN, Basu K, Bota-Rabassedas N, Guo HF, Grzeskowiak CL, Liu X, Yu J, Shi L, Peng DH, Rodriguez BL, Zhang J, Zheng V, Duose DY, Solis LM, Mino B, Raso MG, Behrens C, Wistuba II, Scott KL, Smith M, Nguyen K, Lam G, Choong I, Mazumdar A, Hill JL, Gibbons DL, Brown PH, Russell WK, Shokat K, Creighton CJ, Glenn JS, Kurie JM.

Sci Transl Med. 2020 Jan 22;12(527). pii: eaax3772. doi: 10.1126/scitranslmed.aax3772.

PMID:
31969487
6.

Computational staining of pathology images to study the tumor microenvironment in lung cancer.

Wang S, Rong R, Yang DM, Fujimoto J, Yan S, Cai L, Yang L, Luo D, Behrens C, Parra ER, Yao B, Xu L, Wang T, Zhan X, Wistuba II, Minna J, Xie Y, Xiao G.

Cancer Res. 2020 Jan 8. pii: canres.1629.2019. doi: 10.1158/0008-5472.CAN-19-1629. [Epub ahead of print]

PMID:
31915129
7.

Multifactorial deep learning reveals pan-cancer genomic tumor clusters with distinct immunogenomic landscape and response to immunotherapy.

Xie F, Zhang J, Wang J, Reuben A, Xu W, Yi X, Varn FS, Ye Y, Cheng J, Yu M, Wang Y, Liu Y, Xie M, Du P, Ma K, Ma X, Zhou P, Yang S, Chen Y, Wang G, Xia X, Liao Z, Heymach JV, Wistuba II, Futreal PA, Ye K, Cheng C, Xia T.

Clin Cancer Res. 2020 Jan 7. pii: clincanres.1744.2019. doi: 10.1158/1078-0432.CCR-19-1744. [Epub ahead of print]

PMID:
31911545
8.

Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors.

Strati P, Schlette EJ, Solis Soto L, Dueñas-Hancco DE, Sivina M, Kim E, Keating M, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA.

Blood. 2020 Jan 2. pii: blood.2019003570. doi: 10.1182/blood.2019003570. [Epub ahead of print] No abstract available.

PMID:
31895947
9.

RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer.

Yenerall P, Das AK, Wang S, Kollipara RK, Li LS, Villalobos P, Flaming J, Lin YF, Huffman K, Timmons BC, Gilbreath C, Sonavane R, Kinch LN, Rodriguez-Canales J, Moran C, Behrens C, Hirasawa M, Takata T, Murakami R, Iwanaga K, Chen BPC, Grishin NV, Raj GV, Wistuba II, Minna JD, Kittler R.

Cell Chem Biol. 2020 Jan 16;27(1):105-121.e14. doi: 10.1016/j.chembiol.2019.12.005. Epub 2019 Dec 26.

PMID:
31883965
10.

Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance.

Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR; Lung Cancer Mutation Consortium (LCMC) Pathologist Panel Group.

Appl Immunohistochem Mol Morphol. 2019 Nov 22. doi: 10.1097/PAI.0000000000000810. [Epub ahead of print]

PMID:
31876606
11.

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.

Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, Kerr KM, Yatabe Y, Brambilla E, Longshore J, Papotti M, Sholl LM, Thunnissen E, Rekhtman N, Borczuk A, Bubendorf L, Minami Y, Beasley MB, Botling J, Chen G, Chung JH, Dacic S, Hwang D, Lin D, Moreira A, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Travis W, Yoshida A, Daigneault JB, Wistuba II, Mino-Kenudson M.

J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33847-X. doi: 10.1016/j.jtho.2019.12.107. [Epub ahead of print] Review.

PMID:
31870882
12.

High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.

Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, Wang J, Blando J, Byers LA, Yanamandra N, Brett S, Morley P, Sharma P, Allison J, Wistuba II, Heymach JV.

J Immunother Cancer. 2019 Dec 16;7(1):351. doi: 10.1186/s40425-019-0827-2.

13.

Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.

Jin Y, Bao H, Le X, Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X.

Oncogene. 2019 Dec 12. doi: 10.1038/s41388-019-1143-5. [Epub ahead of print]

PMID:
31831835
14.

TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients.

Villalba M, Exposito F, Pajares MJ, Sainz C, Redrado M, Remirez A, Wistuba I, Behrens C, Jantus-Lewintre E, Camps C, Montuenga LM, Pio R, Lozano MD, de Andrea C, Calvo A.

J Clin Med. 2019 Dec 3;8(12). pii: E2134. doi: 10.3390/jcm8122134.

15.

From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later.

Mulshine JL, Ujhazy P, Antman M, Burgess CM, Kuzmin I, Bunn PA Jr, Johnson BE, Roth JA, Pass HI, Ross SM, Aldige CR, Wistuba II, Minna JD.

J Cell Biochem. 2019 Dec 5. doi: 10.1002/jcb.29564. [Epub ahead of print]

PMID:
31803961
16.

Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC.

Qayyum A, Hwang KP, Stafford J, Verma A, Maru DM, Sandesh S, Sun J, Pestana RC, Avritscher R, Hassan MM, Amin H, Rashid A, Wistuba II, Ehman RL, Ma J, Kaseb AO.

J Immunother Cancer. 2019 Nov 28;7(1):329. doi: 10.1186/s40425-019-0766-y.

17.

ConvPath: A software tool for lung adenocarcinoma digital pathological image analysis aided by a convolutional neural network.

Wang S, Wang T, Yang L, Yang DM, Fujimoto J, Yi F, Luo X, Yang Y, Yao B, Lin S, Moran C, Kalhor N, Weissferdt A, Minna J, Xie Y, Wistuba II, Mao Y, Xiao G.

EBioMedicine. 2019 Dec;50:103-110. doi: 10.1016/j.ebiom.2019.10.033. Epub 2019 Nov 22.

18.

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.

Jin Y, Bao H, Le X, Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X.

Oncogene. 2019 Nov 21. doi: 10.1038/s41388-019-1104-z. [Epub ahead of print] Erratum in: Oncogene. 2019 Dec 12;:.

PMID:
31754213
19.

Mesonephric-like Carcinoma of the Endometrium: A Subset of Endometrial Carcinoma With an Aggressive Behavior.

Euscher ED, Bassett R, Duose DY, Lan C, Wistuba I, Ramondetta L, Ramalingam P, Malpica A.

Am J Surg Pathol. 2019 Nov 12. doi: 10.1097/PAS.0000000000001401. [Epub ahead of print]

PMID:
31725471
20.

The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.

Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas H, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J.

Clin Cancer Res. 2020 Feb 15;26(4):892-901. doi: 10.1158/1078-0432.CCR-19-0556. Epub 2019 Nov 6.

PMID:
31694833

Supplemental Content

Loading ...
Support Center